Neoplasms – Talk Bio

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Global Markets

3 days ago talkbio0Tagged Amgen settlement, Biocon Biologics, Biosimilars, biosimilars approval, bone health, Commission, denosumab, entry - ActRelationshipCheckpoint, Europe market, European (ethnic group), Evfraxy, Neoplasms, Vevzuo

Biocon Biologics; Denosumab biosimilars; Vevzuo; Evfraxy; Europe market entry; Amgen settlement; biosimilars approval; European Commission; bone health; oncology

Tyra Biosciences Strengthens Leadership with Appointment of Bhavesh Ashar as COO and Heather Faulds as CRO

3 days ago talkbio0Tagged Bhavesh Ashar, biology (field), Chief Operating Officer, Chief Regulatory Officer, Drug Development, Fibroblast Growth Factor Receptors, Heather Faulds, Neoplasms, Precision Medicine, regulatory strategy, Tyra Biosciences

Tyra Biosciences; Bhavesh Ashar; Heather Faulds; Chief Operating Officer; Chief Regulatory Officer; oncology; precision medicine; FGFR biology; drug development; regulatory strategy

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

3 days ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

1 week ago talkbio0Tagged 67th, AI-driven, annual, Asymmetric Septal Hypertrophy, Biological Markers, BostonGene, Clinical Trials, Hematology (discipline), immune profiling, meeting, Molecular Profiling, Multiple Myeloma, Neoplasms, Precision - temporal, Stratification

BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology

Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)

1 week ago talkbio0Tagged agentic AI, AI-guided, AWS HealthLake, Clinical Decision Support, DNA Integration, healthcare workflow, Malignant neoplasm of breast, Microsoft Teams, multi-agent systems, Neoplasms, Precision Medicine

agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning

GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches

2 weeks ago talkbio0Tagged AnaptysBio, dostarlimab, Jemperli, License Agreement, Litigation, Malignant neoplasm of endometrium, Neoplasms, royalties, SmithKline Beecham, TESARO

GSK; AnaptysBio; Jemperli; dostarlimab; TESARO; litigation; license agreement; oncology; royalties; endometrial cancer

FDA Breakthrough Designations Lead to Priority Reviews, Report Finds

2 weeks ago talkbio0Tagged biotechnology innovation, Breakthrough Therapy, CDER, Drug Approval, expedited pathway, Identifier, Infrequent, Neoplasms, Priority Review, regulatory science, United States Food and Drug Administration

FDA; breakthrough therapy designation; priority review; drug approval; expedited pathway; biotechnology innovation; rare diseases; oncology; CDER; regulatory science

GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer

2 weeks ago talkbio0Tagged Biotechnology, engagers, hematologic cancers, Immunotherapy, letrozole, Myeloid Progenitor Cells, Neoplasms, preclinical programs, SmithKline Beecham, Solid Neoplasm, strategic collaboration, upfront

GSK; LTZ Therapeutics; myeloid cell engagers; oncology; hematologic cancers; solid tumors; immunotherapy; strategic collaboration; biotechnology; $50 million upfront; preclinical programs

Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

2 weeks ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, CloakLink linker technology, Merck, Neoplasms, SLV-154, SLV-324, Solid Neoplasm, Solve Therapeutics, therapeutic autologous dendritic cells, venture capital, Yosemite

Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

2 weeks ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit